Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug offers hope for Long-Term control of devastating kidney diseases

NCT ID NCT03955445

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is for people who have already been in a related trial for the drug iptacopan. It aims to see how safe and effective the drug is over many years for two rare and serious kidney diseases, C3G and IC-MPGN. The goal is to control the disease, protect kidney function, and reduce protein in the urine over the long term.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Childrens Hospital Colorado

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Col Uni Med Center New York Presby

    RECRUITING

    New York, New York, 10032, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Georgia Nephrology Research Inst

    RECRUITING

    Lawrenceville, Georgia, 30046, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Novartis Investigative Site

    RECRUITING

    CABA, Buenos Aires, C1425AGC, Argentina

  • Novartis Investigative Site

    RECRUITING

    Buenos Aires, W3400ABH, Argentina

  • Novartis Investigative Site

    RECRUITING

    Belo Horizonte, Minas Gerais, 30150-221, Brazil

  • Novartis Investigative Site

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90035-074, Brazil

  • Novartis Investigative Site

    RECRUITING

    Botucatu, São Paulo, 3880-1001, Brazil

  • Novartis Investigative Site

    RECRUITING

    São Paulo, São Paulo, 04038-002, Brazil

  • Novartis Investigative Site

    RECRUITING

    Salvador, 40323-010, Brazil

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

  • Novartis Investigative Site

    RECRUITING

    Beijing, 100034, China

  • Novartis Investigative Site

    RECRUITING

    Shanghai, 200040, China

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Prague, 128 08, Czechia

  • Novartis Investigative Site

    RECRUITING

    Montpellier, 34295, France

  • Novartis Investigative Site

    RECRUITING

    Paris, 75015, France

  • Novartis Investigative Site

    RECRUITING

    Toulouse, 31054, France

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Erlangen, 91054, Germany

  • Novartis Investigative Site

    RECRUITING

    Essen, 45147, Germany

  • Novartis Investigative Site

    RECRUITING

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    RECRUITING

    Mainz, 55131, Germany

  • Novartis Investigative Site

    RECRUITING

    Heraklion Crete., 715 00, Greece

  • Novartis Investigative Site

    RECRUITING

    Thessaloniki, 546 42, Greece

  • Novartis Investigative Site

    RECRUITING

    Petah Tikva, 4920235, Israel

  • Novartis Investigative Site

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Novartis Investigative Site

    RECRUITING

    Ranica, BG, 24020, Italy

  • Novartis Investigative Site

    RECRUITING

    Roma, RM, 00165, Italy

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Nagoya, Aichi-ken, 4668560, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Asahikawa, Hokkaido, 0788510, Japan

  • Novartis Investigative Site

    COMPLETED

    Sapporo, Hokkaido, 0608543, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Takatsuki, Osaka, 569 1192, Japan

  • Novartis Investigative Site

    RECRUITING

    Ohtsu, Shiga, 5202192, Japan

  • Novartis Investigative Site

    RECRUITING

    Hachiōji, Tokyo, 193-0998, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Niigata, 9518520, Japan

  • Novartis Investigative Site

    RECRUITING

    Leiden, South Holland, 2333 ZA, Netherlands

  • Novartis Investigative Site

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28040, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28041, Spain

  • Novartis Investigative Site

    RECRUITING

    Seville, 41009, Spain

  • Novartis Investigative Site

    RECRUITING

    Bern, 3010, Switzerland

  • Novartis Investigative Site

    RECRUITING

    Köseköy, Kocaeli, 41380, Turkey (Türkiye)

  • Novartis Investigative Site

    RECRUITING

    Kayseri, Melikgazi, 38039, Turkey (Türkiye)

  • Novartis Investigative Site

    RECRUITING

    Ankara, Yenimahalle, 06500, Turkey (Türkiye)

  • Novartis Investigative Site

    RECRUITING

    Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Cardiff, CF14 4XW, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    London, W12 0HS, United Kingdom

  • University of Iowa Health Care

    RECRUITING

    Iowa City, Iowa, 52242-1091, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

C3 GLOMERULOPATHY IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS